ArticleBMC bioinformatics2026
C2M-Mamba: drug-drug interaction prediction based on cross-modal cross-Mamba.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Accurately predicting potential drug-drug interactions (DDIs) from multimodal data is critical for medication safety and adverse drug reaction prevention. Existing methods face challenges in modeling long-range dependencies and effectively integrating heterogeneous features from structured molecular data and unstructured text. To address these limitations, we propose C2M-Mamba, a cross-modal framework that integrates convolutional neural networks, Mamba, and cross-Mamba (CroMamba) to capture discriminative features from drug descriptions, SMILES sequences, and social media texts. The model efficiently handles long-range dependencies through state space models while enabling effective cross-modal fusion. Comprehensive evaluations on the DDIExtraction2013 dataset demonstrate that C2M-Mamba outperforms 10 state-of-the-art baselines, achieving 82.37% precision, 80.98% F1-score, and 88.73% AUC. The proposed approach also exhibits robust performance in handling class imbalance and provides interpretable predictions, offering a reliable solution for multimodal DDI prediction with potential applications in pharmacovigilance and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.